[go: up one dir, main page]

CO5700771A2 - Antagonistas del receptor hidroisoindolina taquiquinina - Google Patents

Antagonistas del receptor hidroisoindolina taquiquinina

Info

Publication number
CO5700771A2
CO5700771A2 CO06073837A CO06073837A CO5700771A2 CO 5700771 A2 CO5700771 A2 CO 5700771A2 CO 06073837 A CO06073837 A CO 06073837A CO 06073837 A CO06073837 A CO 06073837A CO 5700771 A2 CO5700771 A2 CO 5700771A2
Authority
CO
Colombia
Prior art keywords
alkyl
taquiquinine
hydroisoindoline
receiver antagonists
antagonists
Prior art date
Application number
CO06073837A
Other languages
English (en)
Inventor
Jaime Lynn Bunda
Robert J Devita
Jinlong Jiang
Sander G Mills
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of CO5700771A2 publication Critical patent/CO5700771A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

1.- Un compuesto de la fórmula I: en el que:R1 se selecciona del grupo que consiste en: (1) hidrógeno, (2) alquilo C1-6, el cual está insustituido o sustituido con halógeno, hidroxilo o fenilo,(3) ciclopentenona, la cual está insustituida o sustituida con hidroxilo, o metilo (4) -(CO)- alquilo C1-6, (5) -(CO)-NH2, (6) -(CO)-NHalquilo C1-6, y (7) -(CO)-N(alquilo C1-6)(alquilo C1-6);X se selecciona independientemente del grupo que consta de: (1) hidrógeno, (2) flúor, y (2) metilo;y sales farmacéuticamente aceptables del mismo y enantiómeros individuales y diastereómeros individuales del mismo.
CO06073837A 2004-01-27 2006-07-27 Antagonistas del receptor hidroisoindolina taquiquinina CO5700771A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53991304P 2004-01-27 2004-01-27
US56122704P 2004-04-09 2004-04-09

Publications (1)

Publication Number Publication Date
CO5700771A2 true CO5700771A2 (es) 2006-11-30

Family

ID=34830494

Family Applications (1)

Application Number Title Priority Date Filing Date
CO06073837A CO5700771A2 (es) 2004-01-27 2006-07-27 Antagonistas del receptor hidroisoindolina taquiquinina

Country Status (31)

Country Link
US (3) US7217731B2 (es)
EP (1) EP1711465B1 (es)
JP (1) JP3987100B2 (es)
KR (1) KR20060127927A (es)
AR (1) AR047439A1 (es)
AT (1) ATE382034T1 (es)
AU (1) AU2005207934B2 (es)
BR (1) BRPI0507050A (es)
CA (1) CA2554550C (es)
CO (1) CO5700771A2 (es)
CR (1) CR8522A (es)
CY (1) CY1107167T1 (es)
DE (1) DE602005004011T2 (es)
DK (1) DK1711465T3 (es)
EA (1) EA010598B1 (es)
EC (1) ECSP066716A (es)
ES (1) ES2297687T3 (es)
GE (1) GEP20094691B (es)
HK (1) HK1100937A1 (es)
HR (1) HRP20080100T3 (es)
IL (1) IL176879A0 (es)
MA (1) MA28359A1 (es)
NI (1) NI200600164A (es)
NO (1) NO339041B1 (es)
NZ (1) NZ548415A (es)
PE (1) PE20050687A1 (es)
PL (1) PL1711465T3 (es)
PT (1) PT1711465E (es)
TW (1) TWI341198B (es)
UA (1) UA84192C2 (es)
WO (1) WO2005073191A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR047439A1 (es) 2004-01-27 2006-01-18 Merck & Co Inc Antagonistas del receptor hidroisoindolina taquiquinina
US7652058B2 (en) 2004-12-14 2010-01-26 Merck Sharp & Dohme Corp. Octahydropyrano[3,4-C]pyrrole tachykinin receptor antagonists
US7683068B2 (en) * 2005-06-27 2010-03-23 Merck Sharp & Dohme Corp. Hydroisoindoline tachykinin receptor antagonists
AU2006269383A1 (en) * 2005-07-11 2007-01-18 Merck Sharp & Dohme Corp. Process for making hydroisoindoline tachykinin receptor antagonists
ATE511842T1 (de) * 2005-10-04 2011-06-15 Merck Sharp & Dohme Kombinationstherapie zur behandlung von erhöhter miktionsfrequenz, akutem harndrang und inkontinenz
EP1965794A4 (en) * 2005-12-22 2009-10-21 Merck & Co Inc OCTAHYDROPYRANO [3,4-c] pyrrole tachykinin receptor Antagonist
US20090042854A1 (en) * 2006-01-24 2009-02-12 Jianming Bao Hexahydro-3H-Pyrrolizin-3-Ones Useful as Tachykinin Receptor Antagonists
CA2662435A1 (en) * 2006-09-06 2008-03-13 Merck & Co., Inc. Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
WO2008054690A2 (en) * 2006-11-02 2008-05-08 Merck & Co., Inc. Polymorphs of a hydroisoindoline tachykinin receptor antagonist
CA2681749A1 (en) * 2007-03-29 2008-10-09 Merck & Co., Inc. Combination therapy for the treatment-of lower urinary tract symptoms
EP2144503B9 (en) * 2007-04-10 2013-09-04 Merck Sharp & Dohme Corp. 4-(octahydro-2H-isoindol-2-yl)-1,3-oxazol-4-one as TACHYKININ RECEPTOR ANTAGONISTS
US8748433B2 (en) 2010-04-30 2014-06-10 Merck Sharp & Dohme Corp. β3 adrenergic receptor agonists
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
EP2729147B1 (en) 2011-07-04 2017-09-06 IRBM - Science Park S.p.A. Nk-1 receptor antagonists for treating corneal neovascularisation
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
BR112015031724A2 (pt) 2013-06-24 2017-07-25 Tigercat Pharma Inc uso do antagonista do receptor nk-1 serlopitant em pruridos
IL312486B1 (en) 2017-04-10 2025-01-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
KR20250004125A (ko) 2017-06-30 2025-01-07 체이스 테라퓨틱스 코포레이션 우울증을 치료하기 위한 nk-1 길항제 조성물 및 우울증 치료에 사용하는 방법
RU2020131446A (ru) 2018-02-26 2022-03-28 Оспедале Сан Раффаэле С.Р.Л. Антагонисты nk-1 для применения в лечении глазной боли
EP4117673A1 (en) 2020-03-11 2023-01-18 Ospedale San Raffaele S.r.l. Treatment of stem cell deficiency
IL296635A (en) 2020-04-03 2022-11-01 Nerre Therapeutics Ltd An nk-1 receptor antagonist for the treatment of a disease selected from sepsis, septic shock, acute respiratory distress syndrome (ARDS), or multiple organ dysfunction syndrome (MODS)
WO2021245512A1 (en) 2020-06-02 2021-12-09 Nerre Therapeutics Limited Neurokinin (nk)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650142A (en) * 1995-09-27 1997-07-22 Church & Dwight Co., Inc. Bicarbonate-containing deodorant cosmetic stick compositions
WO1997014671A1 (en) * 1995-10-18 1997-04-24 Merck & Co., Inc. Cyclopentyl tachykinin receptor antagonists
CN1859914A (zh) 2003-09-30 2006-11-08 默克公司 苯基吡咯烷醚速激肽受体拮抗剂
AR047439A1 (es) * 2004-01-27 2006-01-18 Merck & Co Inc Antagonistas del receptor hidroisoindolina taquiquinina

Also Published As

Publication number Publication date
UA84192C2 (en) 2008-09-25
ECSP066716A (es) 2006-10-31
JP3987100B2 (ja) 2007-10-03
MA28359A1 (fr) 2006-12-01
TWI341198B (en) 2011-05-01
US20080280966A1 (en) 2008-11-13
HRP20080100T3 (en) 2008-04-30
AU2005207934A1 (en) 2005-08-11
NI200600164A (es) 2007-05-29
ES2297687T3 (es) 2008-05-01
PE20050687A1 (es) 2005-09-27
KR20060127927A (ko) 2006-12-13
DK1711465T3 (da) 2008-03-31
CY1107167T1 (el) 2012-10-24
JP2007519728A (ja) 2007-07-19
US20050165083A1 (en) 2005-07-28
NO339041B1 (no) 2016-11-07
US20070161695A1 (en) 2007-07-12
PT1711465E (pt) 2008-02-25
EA010598B1 (ru) 2008-10-30
EP1711465A1 (en) 2006-10-18
NO20063810L (no) 2006-10-26
HK1100937A1 (en) 2007-10-05
DE602005004011T2 (de) 2008-12-11
PL1711465T3 (pl) 2008-05-30
IL176879A0 (en) 2006-10-31
TW200534850A (en) 2005-11-01
CA2554550A1 (en) 2005-08-11
EA200601378A1 (ru) 2007-02-27
CA2554550C (en) 2011-05-03
NZ548415A (en) 2009-11-27
EP1711465B1 (en) 2007-12-26
US7645790B2 (en) 2010-01-12
BRPI0507050A (pt) 2007-06-12
US7217731B2 (en) 2007-05-15
CR8522A (es) 2007-06-06
GEP20094691B (en) 2009-05-25
US7345083B2 (en) 2008-03-18
DE602005004011D1 (de) 2008-02-07
WO2005073191A1 (en) 2005-08-11
ATE382034T1 (de) 2008-01-15
AU2005207934B2 (en) 2010-11-25
AR047439A1 (es) 2006-01-18

Similar Documents

Publication Publication Date Title
CO5700771A2 (es) Antagonistas del receptor hidroisoindolina taquiquinina
HRP20080666T3 (en) Cgrp receptor antagonists
CY1112011T1 (el) Παραγωγα αζαδικυκλο (3.1.0) εξανιου χρησιμα ως ρυθμιστες υποδοχεων d3 ντοπαμινης
HRP20120323T1 (en) Diarylhydantoin compounds
HRP20080027T3 (en) 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide
CO5611139A2 (es) Pirimidinas aril sustituidas y el uso de las mismas
WO2009065919A3 (de) Organische verbindungen
ECSP055913A (es) Inhibidores de las polimerasas víricas
WO2006049835A3 (en) Indole and benzimidazole derivatives
CL2010000204A1 (es) Compuestos intermediarios derivados de 4 amino-3-metoxibenzamida; compuesto intermediario n-{4-[4-(ciclopropilmetil)piperazin-1-il]ciclohexil}acetamida; compuesto intermediario 2-cloro-7-etil-7,8-dihidro-5-metil-8-(1-metiletil)-6(5h)-pteridinona, útiles en la preparación de dihidropteridinonas sustituidas (divisional sol. 2077-05).
WO2009065920A3 (de) Verbindungen
UA94910C2 (ru) Замещенные глицинамиды с антитромбическим действием и ингибирующим действием на фактор ха
NO20032252L (no) Piperazinylpyrazinforbindelser som agonist eller antagonist av serotonin 5HT-2-reseptor
RS51341B (en) INTERMEDIATE COMPOUNDS FOR THE TRANS-5-CHLOR-2-METHYL-2,3A, 12B-TETRAHYDRO-1H-DIBENZE [2,3; 6,7] OXEPINO [4,5-C] Pyrrole
HRP20080529T3 (en) Amide prodrug of gemcitabine, compositions and use thereof
WO2005103037A3 (de) Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
NO20052884L (no) Substituerte indolpyridinforbindelser som anti-infeksjonsmidler.
RS51146B (sr) Novi difenil-azetidinon sa poboljšanim fiziološkim osobinama postupak za njegovu proizvodnju,lekovi koji sadrže ovo jedinjenje i njihova upotreba
AR049883A1 (es) Antagonistas de cgrp seleccionados, procedimientos para su preparacion, y su empleo como medicamentos
MX2010003849A (es) Antagonistas de cgrp.
NO20076680L (no) Utvalgte CGRP-antagonister, metoder for fremstilling av disse og deres anvendelse som medikamenter
EA200801365A1 (ru) Замещенные 5-фенил-3,6-дигидро-2-оксо-6h-1,3,4-тиадиазины
DK1753723T3 (da) Substituerede quinolinderivater som mitotiske kinesininhibitorer
RS53622B1 (en) TETRAHYDROFURANIL UNITS DISCUSSIONED AS BRADIKININ-B1 ANTAGONISTS
BR0208812A (pt) Derivados fenil heterociclil éter como inibidores de recaptação de serotonina

Legal Events

Date Code Title Description
FG Application granted